Tandem Diabetes Care, Inc. $TNDM Shares Sold by Brown Capital Management LLC

Brown Capital Management LLC lowered its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 34.1% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 363,352 shares of the medical device company’s stock after selling 187,855 shares during the period. Brown Capital Management LLC’s holdings in Tandem Diabetes Care were worth $4,411,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Hood River Capital Management LLC boosted its position in shares of Tandem Diabetes Care by 10.9% during the 2nd quarter. Hood River Capital Management LLC now owns 2,564,978 shares of the medical device company’s stock valued at $47,811,000 after purchasing an additional 252,934 shares in the last quarter. Paradice Investment Management LLC lifted its stake in Tandem Diabetes Care by 24.3% during the third quarter. Paradice Investment Management LLC now owns 2,196,468 shares of the medical device company’s stock valued at $26,665,000 after purchasing an additional 429,289 shares during the last quarter. Stephens Investment Management Group LLC boosted its holdings in Tandem Diabetes Care by 1.8% during the second quarter. Stephens Investment Management Group LLC now owns 1,737,769 shares of the medical device company’s stock worth $32,392,000 after buying an additional 30,854 shares in the last quarter. Jennison Associates LLC boosted its holdings in Tandem Diabetes Care by 12.3% during the second quarter. Jennison Associates LLC now owns 1,658,942 shares of the medical device company’s stock worth $30,923,000 after buying an additional 181,834 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Tandem Diabetes Care by 3.2% in the second quarter. Geode Capital Management LLC now owns 1,606,336 shares of the medical device company’s stock worth $29,946,000 after buying an additional 49,126 shares during the last quarter.

Tandem Diabetes Care Trading Up 1.0%

Shares of NASDAQ TNDM opened at $20.09 on Tuesday. The company has a current ratio of 2.44, a quick ratio of 1.90 and a debt-to-equity ratio of 2.33. Tandem Diabetes Care, Inc. has a one year low of $9.98 and a one year high of $37.78. The business has a 50-day moving average price of $21.29 and a two-hundred day moving average price of $16.66. The firm has a market capitalization of $1.36 billion, a PE ratio of -6.59 and a beta of 1.68.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Thursday, November 6th. The medical device company reported ($0.31) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.31). The business had revenue of $249.25 million during the quarter, compared to analyst estimates of $235.80 million. Tandem Diabetes Care had a negative net margin of 20.19% and a negative return on equity of 73.97%. The firm’s revenue was up 2.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.35) earnings per share. As a group, analysts predict that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Canaccord Genuity Group set a $35.00 price objective on Tandem Diabetes Care and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Mizuho upped their target price on Tandem Diabetes Care from $18.00 to $21.00 and gave the company a “neutral” rating in a report on Wednesday, December 17th. Robert W. Baird set a $30.00 price target on Tandem Diabetes Care and gave the stock an “outperform” rating in a research note on Tuesday, December 16th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Tandem Diabetes Care in a research note on Wednesday, December 17th. Finally, Stifel Nicolaus assumed coverage on shares of Tandem Diabetes Care in a report on Tuesday, October 21st. They issued a “hold” rating and a $15.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $24.06.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.